[
    {
        "text": "let's shift gears a little bit and talk about the clinical trial landscape because that's a very big part of what you do right you're a clinical psychiatrist who deals with patients on an individual basis as we've discussed but you also are heavily involved in another part of this which is how to do clinical trials and this is obviously a very important part of this work now alzheimer's disease and drugs don't have a great marriage they don't have a great track record the way cardiovascular disease does and even though oncology is not you know great far from perfect uh oncology even has a better track record than alzheimer's disease and i think you could make the case without being hyperbolic that there is no disease that has a worse track record um relative to the inputs uh on the output side in other words there were you know there are orphan diseases for which we have no drugs right but there have been few shots on goal so the ratio of shots on goals shots on goal to goals is lower in alzheimer's disease than probably not probably unquestionably any other disease okay on the one level that undoubtedly speaks to the complexity of the disease some might argue that on another level that speaks to the wrong goal or shooting too late in the game you know shooting from too bad an angle at the wrong goal like you could take this metaphor 10 different ways um as it stands today there are about 120 drugs in the pipeline um if my number crunching has it right about 27 of them if we extracted this correctly off",
        "start": "00:00:00",
        "duration": 192.278,
        "title": "Drug pipeline, clinical trials, and major challenges to overcome in Alzheimer’s disease"
    },
    {
        "text": "clinicaltrials.gov are in phase one so for the listener meaning these are drugs that are really just being evaluated for safety at this point so we have some animal data that suggests this is a good idea we have no idea if it works in humans but in in a very small way with dose escalation we want to make sure it's safe about 65 are in phase two so that means they've passed that bar of being safe or at least safe enough to proceed to phase two where now we're looking for some efficacy and will of course continue to monitor safety and then 29 are in phase 3 which means at a small scale they've shown efficacy typically against a placebo now we want to see if there's efficacy again either versus a placebo or ideally against a current standard in a larger trial where again we're always going to continue to monitor safety but it's really this third stage that is required for fda approval another way to slice the data is to look at it by category of drug and i found this to be the most interesting 12 of these are in the space of cognitive enhancement 12 are in the space of neuropsychiatric and behavioral improvement and 97 are in the space of disease modification can you explain a little bit what the differences of those three categories mean and uh knowing that the next question i'm going to ask you is that how has that evolved over the last 20 years because that to me has been the big that was the thing i was most surprised by yeah so the um the symptomatic treatments are ones that you know can help slow cognitive decline or help improve",
        "start": "00:01:37",
        "duration": 203.159,
        "title": "Drug pipeline, clinical trials, and major challenges to overcome in Alzheimer’s disease"
    },
    {
        "text": "memory and thinking but are not targeting the underlying disease process so all the drugs that we currently have on the market are ones that are symptomatic treatments because they're just helping those neurons communicate in the case of xenepazil and glantamine and ribostigmine they're you know cholinesterase inhibitors and then there's mementine which is an nmda receptor antagonist that that normalizes levels of glutamate but they're just they're helping with neurotransmitters and they're not um targeting the underlying pathology of amyloid and tau then obviously the behavioral drugs are ones that are being targeted for specific behavior problems in alzheimer's and other dementia patients things like apathy agitation psychosis sometimes sleep issues sometimes even appetite and eating problems so those all kind of fall under the behavioral umbrella and then these disease modifying treatments are ones that actually target the underlying pathology in the case of sort of the biggest group of those that are in trials right now are really monoclonal antibodies against primarily amyloid but also if you look you know targeting tau and removing them from the brain in the hopes that then there will be cognitive improvement or at least halting cognitive decline um can i interject for a second mechanistically um is it known exactly where amyloid beta is made is it is it understood how you know from where the where the transcription takes place or",
        "start": "00:03:19",
        "duration": 233.04000000000002,
        "title": "Drug pipeline, clinical trials, and major challenges to overcome in Alzheimer’s disease"
    },
    {
        "text": "is this all post-translational modification well so there there's a whole science dedicated to that you know and there it actually is is different points along the cascade you know so there's the amyloid precursor protein which is on chromosome 21 which is why people with down syndrome who have three copies of chromosome 21 almost inevitably will get alzheimer's if they live long enough because they're making a third more amyloid than the rest of us so anywhere from the very beginning of our dna all the way through some of the enzymes that cleave amyloid so part of the problem is that the amyloid gets cleaved at a length of 40 or 42 amino acids rather than whatever it's supposed to be which i don't remember and then the abnormal amyloid kind of folds and you know there's fibrils and there there's pla you know the plaque itself is a conglomeration of um a series of folds in the protein and so um there are even differences among the antibodies as to what part of that cascade they target and amyloid is not necessary in other words if you could wave a magic wand and pull amyloid out of a person is there any ill consequence well like i said it is part of blood vessel walls normally so it is this pathologic amyloid you know these abnormal lengths of a beta 40 and 42 um yeah i mean those could be pulled out without consequence because they shouldn't be there in the first place so if you wanted to target the system you would not target you would not target the creation of amyloid you would",
        "start": "00:05:15",
        "duration": 246.56199999999998,
        "title": "Drug pipeline, clinical trials, and major challenges to overcome in Alzheimer’s disease"
    },
    {
        "text": "probably target the enzymes that abnormally cleave well that that is one area that has been studied um the gamma-secretase inhibitors for example are ones that have been studied um there's there's then the base inhibitors these are are things that are being looked at because these are responsible for cleaving but a lot of times those have had side effects that we didn't really want yeah i wonder if has anybody looked at something like an antisense oligonucleotide that goes straight after the enzyme in a laser precision basically says you can't make this enzyme and you don't have to carpet bomb the enzyme and everything around it you're literally going after the transcription of the enzyme yeah i honestly don't know you know that's that's for the scientists i mean i'm sure somebody has thought of it and declined there's i'm sure there's a reason that hasn't been yeah i mean the thing is you know sometimes they have thought of it or they've tried it but then they don't realize what the downstream effects of doing so may be yeah um and that's been a problem with several of these medications you know whether it's a great idea you know they've identified a target they've identified compounds that seek out that target but they cause liver toxicity or they cause you know some other significant medical issue or they cause cardiac arrhythmias or um things that medically are not safe to continue so the thing that surprised me amanda",
        "start": "00:07:21",
        "duration": 220.3199999999999,
        "title": "Drug pipeline, clinical trials, and major challenges to overcome in Alzheimer’s disease"
    },
    {
        "text": "when i looked at the distribution of drugs just again this is available on clinicaltrials.gov is that 80 percent of the drugs are disease modifying drugs which is a good sign of course because the other 20 as you said are symptomatic now that's not the way the drugs are currently represented there are are there how many drugs six approved drugs for alzheimer's disease right now well there's technically five well yes there's six but one of them is a combination of two existing right okay this podcast is for general informational purposes only and does not constitute the practice of medicine nursing or other professional health care services including the giving of medical advice no doctor-patient relationship is formed the use of this information and the materials linked to this podcast is at the user's own risk the content on this podcast is not intended to be a substitute for professional medical advice diagnosis or treatment users should not disregard or delay in obtaining medical advice from any medical condition they have and they should seek the assistance of their health care professionals for any such conditions finally i take conflicts of interest very seriously for all of my disclosures and the companies i invest in or advise please visit peteratiammd.com forward slash about where i keep an up-to-date and active list of such companies",
        "start": "00:09:12",
        "duration": 186.48,
        "title": "Drug pipeline, clinical trials, and major challenges to overcome in Alzheimer’s disease"
    }
]